Xenografting of human umbilical mesenchymal stem cells from Wharton's jelly ameliorates mouse spinocerebellar ataxia type 1
- PMID: 31508229
- PMCID: PMC6727337
- DOI: 10.1186/s40035-019-0166-8
Xenografting of human umbilical mesenchymal stem cells from Wharton's jelly ameliorates mouse spinocerebellar ataxia type 1
Abstract
Background: Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by the expansion of CAG repeats in ATXN1 gene resulting in an expansion of polyglutamine repeats in the ATXN1 protein. Unfortunately, there has yet been any effective treatment so far for SCA1. This study investigated the feasibility of transplanting human umbilical mesenchymal stem cells (HUMSCs) into transgenic SCA1 mice containing an expanded uninterrupted allele with 82 repeats in the ATXN1-coding region.
Methods: 106 human umbilical mesenchymal stem cells were transplanted into the cerebella at 1 month of age.
Results: HUMSCs displayed significant ameliorating effects in SCA1 mice in terms of motor behaviors in balance beam test and open field test as compared with the untransplanted SCA1 mice. HUMSCs transplantation effectively reduced the cerebellar atrophy, salvaged Purkinje cell death, and alleviated molecular layer shrinkage. Electrophysiological studies showed higher amplitudes of compound motor action potentials as indicated by increasing neuronal-muscular response strength to stimuli after stem cell transplantation. At 5 months after transplantation, HUMSCs scattering in the mice cerebella remained viable and secreted cytokines without differentiating into neuronal or glia cells.
Conclusions: Our findings provide hope for a new therapeutic direction for the treatment of SCA1.
Keywords: Cell transplantation; SCA1; Umbilical mesenchymal stem cells.
Conflict of interest statement
Competing interestsThe authors declare that they have no competing interests.
Figures






Similar articles
-
Therapeutic Strategies for Spinocerebellar Ataxia Type 1.Biomolecules. 2023 May 2;13(5):788. doi: 10.3390/biom13050788. Biomolecules. 2023. PMID: 37238658 Free PMC article. Review.
-
Single nuclei RNA sequencing investigation of the Purkinje cell and glial changes in the cerebellum of transgenic Spinocerebellar ataxia type 1 mice.Front Cell Neurosci. 2022 Nov 15;16:998408. doi: 10.3389/fncel.2022.998408. eCollection 2022. Front Cell Neurosci. 2022. PMID: 36457352 Free PMC article.
-
Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly.Theranostics. 2019 Sep 17;9(22):6646-6664. doi: 10.7150/thno.33741. eCollection 2019. Theranostics. 2019. PMID: 31588241 Free PMC article.
-
Indirect Negative Effect of Mutant Ataxin-1 on Short- and Long-Term Synaptic Plasticity in Mouse Models of Spinocerebellar Ataxia Type 1.Cells. 2022 Jul 20;11(14):2247. doi: 10.3390/cells11142247. Cells. 2022. PMID: 35883691 Free PMC article.
-
Progress in pathogenesis studies of spinocerebellar ataxia type 1.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1079-81. doi: 10.1098/rstb.1999.0462. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434309 Free PMC article. Review.
Cited by
-
Human Umbilical Mesenchymal Stem Cell Xenografts Repair UV-Induced Photokeratitis in a Rat Model.Biomedicines. 2022 May 12;10(5):1125. doi: 10.3390/biomedicines10051125. Biomedicines. 2022. PMID: 35625862 Free PMC article.
-
Spinocerebellar ataxias: from pathogenesis to recent therapeutic advances.Front Neurosci. 2024 Jun 4;18:1422442. doi: 10.3389/fnins.2024.1422442. eCollection 2024. Front Neurosci. 2024. PMID: 38894941 Free PMC article. Review.
-
Xenograft of Human Umbilical Mesenchymal Stem Cells Promotes Recovery from Chronic Ischemic Stroke in Rats.Int J Mol Sci. 2022 Mar 15;23(6):3149. doi: 10.3390/ijms23063149. Int J Mol Sci. 2022. PMID: 35328574 Free PMC article.
-
Comparison between the therapeutic effects of differentiated and undifferentiated Wharton's jelly mesenchymal stem cells in rats with streptozotocin-induced diabetes.World J Stem Cells. 2020 Feb 26;12(2):139-151. doi: 10.4252/wjsc.v12.i2.139. World J Stem Cells. 2020. PMID: 32184938 Free PMC article.
-
Therapeutic Strategies for Spinocerebellar Ataxia Type 1.Biomolecules. 2023 May 2;13(5):788. doi: 10.3390/biom13050788. Biomolecules. 2023. PMID: 37238658 Free PMC article. Review.
References
-
- Soong BW, Morrison PJ. The cerebellum disorders and treatment. In: Manto M, Huisman TAGM, editors. Handbook of clinical neurology, Vol. 155 (3rd series), Chapter 10: Spinocerebellar ataxias. Amsterdam: Elsevier; 2018. p. 143–74. - PubMed
-
- Banfi S, Chung MY, Kwiatkowski TJ, Jr, Ranum LP, McCall AE, Chinault AC, Orr HT, Zoghbi HY. Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb. Genomics. 1993;18(3):627–635. doi: 10.1016/S0888-7543(05)80365-9. - DOI - PubMed
LinkOut - more resources
Full Text Sources